Merck, Lycera broaden partnership on autoimmune disease drugs

Merck & Co. expanded a collaboration with Lycera to develop and market small-molecule drugs against autoimmune diseases. The deal entitles Lycera to an undisclosed upfront fee and research support plus more than $300 million in possible milestone fees, plus royalties. Merck will handle clinical development, and will get the global rights to marketing.

View Full Article in:

Genetic Engineering & Biotechnology News · Crain's Detroit Business (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC